Lenvima (lenvatinib) — United Healthcare
Advanced renal cell carcinoma (RCC)
Preferred products
- Afinitor (everolimus)
- Keytruda (pembrolizumab)
- Avastin (bevacizumab)
- Votrient (pazopanib)
- Sutent (sunitinib)
- Nexavar (sorafenib)
Initial criteria
- Diagnosis of advanced renal cell carcinoma
- One of the following:
- Both of the following: History of failure, contraindication, or intolerance to prior antiangiogenic therapy [e.g., Avastin (bevacizumab), Votrient (pazopanib), Sutent (sunitinib), Nexavar (sorafenib)] AND Used in combination with Afinitor (everolimus)
- OR Used in combination with Keytruda (pembrolizumab)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lenvima therapy
- Used in combination with Afinitor (everolimus) or Keytruda (pembrolizumab)
Approval duration
12 months